drugset / Trial / NCT05977907
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Phase 2
Recruiting
30 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
IO Biotech · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Timeline
- Start
- 2023-12-14
- Primary completion
- 2026-10-16
- Completion
- 2028-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IO102-103 | Unknown | — | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |